Top Markets
Coin of the day
Addex Therapeutics Ltd Addex Therapeutics Ltd

Addex Therapeutics Ltd

ADXN
Rang in aandelen #33372
Addex Therapeutics Ltd, a biopharmaceutical company in its development phase,... Addex Therapeutics Ltd, a biopharmaceutical company in its development phase, specializes in the discovery, progression, and commercialization of small-molecule pharmaceutical products designed to address central nervous system (CNS) conditions. Based in Geneva, Switzerland, the firm's core research centers on identifying oral small molecule allosteric modulators that interact with G-protein coupled receptors. Its leading clinical programs feature Dipraglurant, intended for the treatment of levodopa-induced dyskinesia in Parkinson's disease and dystonia; ADX71149, targeting epilepsy and various other neurological disorders; and GABAB PAM, developed to combat addiction. Addex has established strategic licensing and collaborative partnerships with organizations including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002, the company changed its name from Addex Pharmaceuticals Ltd to its current designation in March 2012.
Aandeelprijs
$0.05124204
Marktkapitalisatie
$7.78M
Verandering (1 dag)
0.51%
Verandering (1 jaar)
-23.73%
Land
CH
Handel Addex Therapeutics Ltd (ADXN)

Categorie

Winst voor Addex Therapeutics Ltd (ADXN)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Addex Therapeutics Ltd bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Addex Therapeutics Ltd van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE